• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The Impact of the Phase III Pipeline – Future Projections and Market Disruptions

$3,500.00 – $7,000.00

Clear
SKU: KLI1187684 Categories: Drug Delivery Market Reports, Pharmaceuticals Market Research Pages: 480
  • Description
  • Table of Contents
  • Latest reports

Description

There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult forecasting projects in market research.

In this nearly 500-page analysis, Kalorama Information has compiled all the relevant information about the candidates, their value, and their likely impact. And we’ve made some predictions and estimates of the changing market scenarios in five therapeutic areas.

In particular, this report examines over 500 drugs in Phase III clinical trials and how these new products are expected to perform and affect existing markets. The report looks at five therapeutic categories:

  • Cardiovascular disease,
  • Neuropsychotherapeutic disorders,
  • Infectious disease,
  • Cancer, and
  • Others.

Market opportunity revenues are provided in each segment for approvals anticipated from 2006 to 2010 with specific information related to likely 2006 approvals. For each segment, the report includes an

  • Overview,
  • Descriptions of products in phase III development,
  • Number of approvals expected each year through 2010 by indication within the segment,
  • Market forecasts for those likely to be approved,
  • Which major brands and marketers who are currently active the segment will be affected by these likely new entrants, and
  • What share of the segments these new drugs are likely to take.

This report is the only analysis of its kind available in syndicated form and contains vital intelligence for strategic planners within the industry and analysts and investors interested in the competitive dynamics in the years ahead.

Table of Contents

Chapter One: Executive Summary

  • Scope and Methodology
  • Potential Market Opportunity
  • Issues and Trends Affecting Market
  • Leading Competitors

Chapter Two: Introduction Drugs in Phase III Development

  • Introduction
  • Drug Development Overview
    • Phases of Drug Development
    • Benefits and Risks of Phase III Development
    • Benefits
    • Risks
    • Randomization
    • Clinical Trial Protocol
  • Orphan Drugs
  • Fast Track Drug Status
  • Biotechnology Drug Development
  • Mergers, Acquisitions, and Collaborations
  • Contributors To R&D Success
  • R&D Spending
    • Contract Research Organizations

Chapter Three: Cardiovascular Drugs: Phase III Development Analysis

  • Overview
    • Heart
    • Circulatory System
    • Cardiac Cycle
    • Isovolumic Contraction
    • Ventricular Ejection
    • Isovolumic Relaxation
    • Coronary Circulation
    • Cardiac Myocytes
    • Contraction
    • Calcium Role in Contraction
    • Relaxation
    • Cardiac Energy Metabolism
    • Cardiac Output
    • Conditions
    • Angina Pectoris
    • Arrhythmia
    • Atherosclerosis
    • Congestive Heart Failure
    • Coronary Artery Disease
    • Hypertension
    • Myocardial Infarction
    • Incidence of Conditions
  • Products in Development
    • AGI-1067
    • Alfimeprase
    • Ambrisentan
    • Angiomax
    • Atrixra
    • Azimilide
    • Celacade
    • Clevelox
    • Conivaptan
    • CP-529, 414 (Torcetrapib/Atorvastatin)
    • Dabigatran Extexilate
    • Darusentan
    • Dronedarone
    • Exanta
    • Enoximone capsules
    • Idraparinux
    • Integrilin
    • Lercanidipine (Zanidip)
    • OPC-41061
    • Pexelizumab
    • Prasugrel
    • Propiony-l-carnitine
    • Ranexa
    • Resten NG
    • RSD 1235 IV
    • Simdax
    • SPP101
    • Tecadenoson
    • Tedisamil (Pulzium)
    • Thelin
  • Market Size and Growth
  • Competitive Analysis

Chapter Four: Neuropsychotherapeutic Drugs: Phase III Development Analysis

  • Overview
    • Structural Organization of the Neurological System
  • Types of Neuropsychotherapeutic Diseases and Disorders
    • Alzheimer’s Disease and Dementia
    • Traumatic Brain Injury
    • Cerebrovascular Disease and Stroke
    • Ischemic Stroke
    • Hemorrhagic Stroke
    • Cerebral Palsy
    • Parkinson’s Disease
    • Huntington’s Disease
    • Myasthenia Gravis
    • Tic and Tourette’s Syndrome
    • Periodic Limb Movement Disorder and Restless Leg Syndrome
    • Seizures
    • Generalized Seizures
    • Partial Seizures
    • Aura/Prodrome
    • Multiple Sclerosis
    • Amyotrophic Lateral Sclerosis
    • Spinal Cord Injury
    • Guillian-Barre Syndrome
    • Bell’s Palsy
    • Anxiety Disorders
    • Panic Disorder
    • Post-traumatic Stress Disorder
    • Specific and Social Phobias
    • Attention Deficit Hyperactivity Disorder
    • Bipolar Disorder
    • Cyclothymic Disorder
    • Borderline Personality Disorder
    • Depression
    • Eating Disorders
    • Anorexia Nervosa
    • Bulimia Nervosa
    • Obsessive-Compulsive Disorder
    • Schizophrenia
    • Sleep Disorders
    • Insomnia
    • Narcolepsy
    • Parasomnia
    • Substance Abuse
    • Alcohol Abuse
    • Drug Abuse
    • Incidence of Conditions
  • Products in Development
    • AERx Inhaled Morphine
    • Alcar
    • ALGRX 3268
    • Alzhemed
    • Ampligen
    • Antegren
    • Aquavan
    • Asenapine
    • Bicifadine
    • Bifeprunox
    • CEP 1347
    • Cerovive
    • Chronogesic
    • Citicoline
    • Corlux
    • DAS-431
    • DU 127090
    • DVS-223
    • Dynastat
    • Fampridine
    • Flurizan
    • Gaboxadol
    • Iloperidone
    • Indiplon
    • KW-6002
    • Lacosamide
    • Miraxion
    • MT 100
    • MT 300
    • Mylinax
    • Neurodex
    • NGX-4010
    • NRP104
    • Nuvigil
    • ONO-2506
    • Org 25969
    • Oxytrex
    • Pagoclone
    • Phenserine
    • PRX-00023
    • Rapinyl
    • Rasagiline
    • Remoxy
    • ReoPro
    • Requip CR
    • Rotigotine CDS
    • Saredutant
    • SGS111
    • Silenor
    • SLV308
    • SPD 503
    • Spheramine
    • SR58611
    • Teriflunomide
    • Tramadol
    • Trexima
    • Xaliproden
    • Zelpar
  • Market Size and Growth
  • Competitive Analysis

Chapter Five: Infectious Disease: Phase III Development Analysis

  • Overview
  • Conditions
    • Fungi
    • Viruses
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis D
    • Hepatitis E
    • Hepatitis G
    • Herpes Simplex
    • Epstein-Barr Virus (Mononucleosis)
    • Influenza
    • Other Significant Viruses
    • Human Papilloma Virus
    • Cytomegalovirus
    • Respiratory Syncytial Virus
    • Hantavirus
    • Yellow Fever
    • Rotavirus
    • Parvovirus
    • Incidence of Conditions
    • Products in Development
      • ABT-773
      • ACAM2000
      • Amoxicillin PULSYS
      • Anidulafungin
      • Aplaviroc
      • AzaSite
      • Aztreonam Lysinate
      • Buffer Gel
      • Ceftobiprole (BAL5788)
      • Cervarix
      • Cubicin (daptomycin for injection)
      • Dalbavancin
      • Doripenem
      • Extina
      • Faropenem daloxate
      • Gardasil
      • Garenoxacin
      • Helicide
      • Hyphanox
      • IFN-alpha Lozenge
      • Influvac TC
      • Iseganan
      • Interferon Alfacon/Ribaviron Combination
      • Macrotac
      • ME-609
      • Maraviroc
      • Multiferon
      • MX-226 (CPI-226)
      • Neuprex
      • Noxafil
      • Oracea
      • Oritavancin
      • PolyphenonE Ointment
      • PRO 2000
      • Ramoplanin
      • Retapamulin
      • Rotarix
      • SAVVY
      • Simplirix
      • SPO1A
      • StaphVAX
      • Streptorix
      • T-3811
      • Telavancin
      • Telbivudine
      • Tifacogin
      • Tolevamer
      • Tripranavir
      • Ushercell
      • Veronate
      • Viramidine
      • Zadaxin
    • Market Size and Growth
    • Competitive Analysis

Chapter Six: Cancer Drugs: Phase III Development Analysis

  • Overview
    • Biochemistry of Cancer Cells
    • Carcinogen Metabolism
    • Causes of Cancer Growth
    • Environmental Factors, DNA, RNA
    • Cellular Oncogenes
    • Tumor Suppressor Genes
    • Types of Cancer
    • Bladder/Urinary Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Endometrial (Uterine) Cancer
    • Esophageal Cancer
    • Head and Neck
    • Kidney
    • Leukemia
    • Liver
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Multiple Myeloma
    • Neuroblastoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Incidence of Conditions
    • Products in Development
      • Acapodene
      • Advexin
      • Allovectin-7
      • Alvocidib
      • AMD-3100 (Mozobil)
      • Arzoxifene
      • Atamestane
      • Avastin
      • Avicine
      • Biovaxid
      • Canvaxin
      • Ceplene
      • Cintredekin besudotox (IL13-PE38)
      • Cloretazine
      • CoFactor
      • Cotara
      • DCVAX -Prostate
      • Doxil
      • DTI 015
      • Edotecarin
      • Efaproxyn
      • FavId
      • Genasense
      • Glufosfamide
      • GMK Therapeutics Vaccine
      • GVAX Prostate
      • HuMax CD4
      • IGN101
      • Insegia
      • Ixabepilone
      • Javlor
      • Junovan
      • Lapatinib
      • Lasofoxifene
      • MDX-010
      • MyVax
      • Neovastat
      • Nexavar (previously BAY 43-9006) (Sorafinib)
      • NOV-022
      • Onconase
      • Oncophage
      • OncoVax
      • Orathecin
      • OvaRex
      • Panitumumab
      • Panvac-VF
      • Rencarex
      • Satraplatin
      • Sipuleucel-T (Provenge)
      • STR
      • Tavocept
      • Taxoprexin
      • Telcyta
      • Temsirolimus
      • TheraCIMhR3(Nimotuzunab)
      • Thymitaq
      • TransMID-R
      • Vatalanib
      • Vinorelbine IV
      • Xcytrin
      • Xerecept
      • XL119
      • Xorane
      • XRP9881
      • Xyotax
      • Yondelis
      • Zactima
      • Zarnestra
      • ZYC101a
    • Market Size and Growth
    • Competitive Analysis

Chapter Seven: Other Drugs: Phase III Development Analysis

  • Overview
  • Conditions
    • Types of Conditions, Diseases and Disorders
    • Diabetes
    • Irritable Bowel Syndrome /Crohn’s Disease
    • Psoriasis
    • Rheumatoid Arthritis
    • Osteoporosis
    • COPD/Asthma
    • Incidence of Conditions
    • Products in Development
      • 406381
      • Aclasta
      • Acomplia
      • AERx iDMS
      • Alicaforsen
      • Alista
      • Allermist
      • Alprox TD
      • Alvesco
      • ALX-0600
      • AMG 162 (Denosumab)
      • Aridol
      • Arxxant
      • Arformoterol
      • Asoprisnil
      • Axokine
      • Bazedoxifene
      • Belatacept
      • Bio-E-Gel
      • Biopten
      • Bronchitol
      • CDP 870
      • Ceprotin
      • Chrysalin
      • Cilansetron
      • Cimzia
      • Cordase
      • CS-917
      • Dapoxetine
      • Daxas
      • DE-085
      • Dexloxiglumide
      • DPP4 Inhibitor Oral(Saxasliptin)
      • E2/DNG Pill
      • Eculizumab
      • Evamist
      • Exanatide
      • Exubera
      • FC Patch
      • Ferumoxytol
      • Fersterodine
      • FIBRILLEX
      • Formoterol HFA ( Fordil Certihaler)
      • Fortigel
      • Galida
      • Human Growth Hormone
      • ICA-17043
      • IoGen
      • ISV-205
      • Itax
      • LAF237
      • Lasofoxifene (Oporia)
      • LEA29Y
      • LibiGel
      • Librel
      • Livial
      • Lucentis
      • Menopausal Levonorgestrel System
      • Mepolizumab
      • Methylnaltrexone
      • MK-0431(Sitagliptin)
      • Muraglitazar (Pargluva)
      • NovoMix 50 and 70
      • Onercept
      • OPC-6535
      • Oral Calcitonin
      • OrBec
      • Oxygent
      • Pennsaid Topical Solution
      • Phenoptin
      • PhotoPoint
      • PHP
      • Posurdex
      • PREOS
      • Prexige
      • Primolux
      • PTI-901
      • QAB149
      • Rebamipide
      • ReFacto AF
      • Retanne
      • SPD 476
      • SPI-0211/RU0211 (Lubiprostone)
      • SR 121463
      • Stannsoporfin (Stanate)
      • Starlix and Diovan
      • Tanaproget
      • Teduglutide
      • Terlipressin
      • Tolevamer
      • Tostrelle
      • VP002
      • XP12B
      • YAZ
      • Zelnorm
    • Market Size and Growth
    • Competitive Analysis

 

    The Market for Needle-Free Drug Delivery Systems
    July 14, 2016
    Transdermal and Transmucosal Drug Delivery Markets: Forecasts to 2020
    November 25, 2015
    The World Market for Implantable and Needle-Free Drug Delivery Systems
    December 11, 2013
    The World Market for Transdermal Drug Delivery
    September 13, 2012

Related products

  • Placeholder image

    Rheumatoid Arthritis: The 45 Market in the United States for Drugs and Biologics

    $2,246.00 – $4,492.00
  • Placeholder image

    Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline

    $3,500.00 – $7,000.00
  • Placeholder image

    OTC Women’s Health: A Supplement to Women’s Health, 3rd Edition

    $1,496.00 – $2,992.00
  • Placeholder image

    World Market for Anti-infectives Volume II: The World Market for Antibacterial Medications, The

    $2,500.00 – $5,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Medical Imaging Markets, Volume I: Radiography (X-Ray, Digital X-Ray, Fluoroscopy,...The Worldwide Market for In Vitro Diagnostic Tests, 5th Edition
Scroll to top